Compare Eli Lilly And Co (LLY) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Abrdn Physical Platinum Shares ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Abrdn Physical Platinum Shares ETF trades at $15.25 (market cap $1.93B). The key difference: Eli Lilly And Co is far larger — about 538.9× Abrdn Physical Platinum Shares ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| LLY | PPLT | |
|---|---|---|
Market Cap | $1.04T | $1.93B |
Volume | 3,064,878 | 1,698,523 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.28K | $25.23 |
52-Week Low | $799.57 | $13.73 |
Typical Hold Time | 93 Days | 42 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.25 with a 3.18% daily gain, though technical indicators signal a bearish trend with moving averages unanimously negative. The ETF's fundamental metrics are unavailable in standard financial databases as it tracks physical platinum rather than operating as a traditional company. Recent news highlights platinum's underperformance relative to other precious metals, with mixed signals between bearish term structure and potential seasonal recovery opportunities.
The outlook remains cautious with technical weakness offset by potential catch-up trade opportunities. Key risks include platinum supply dynamics and precious metals market volatility, while the neutral oscillator readings suggest limited near-term momentum. Investment appeal hinges on macroeconomic factors driving platinum demand rather than traditional equity fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
